#USA #Las Vegas #Insmed #BofA Securities #Health Care Conference

Insmed to Present at the BofA Securities 2025 Health Care Conference

Insmed Incorporated, a prominent global biopharmaceutical company, has revealed its intent to present at the BofA Securities 2025 Health Care Conference, slated for May 13, 2025, in Las Vegas. The company's commitment lies deeply rooted in developing innovative therapies aimed at transforming the lives of patients grappling with severe health challenges. The presentation is scheduled for 2:20 PM Pacific Time.

Attendees and stakeholders interested in the latest developments in Insmed’s pipeline will have an opportunity to witness the management team discuss updates on their therapeutic innovations. The entire session will be accessible via a live webcast, allowing investors and the general public alike to engage with the insights being shared. For those unable to attend, the webcast will be archived on Insmed's website for 30 days post-event, ensuring widespread accessibility to the information presented.

About Insmed Incorporated

Founded with a mission to prioritize people, Insmed is at the forefront of the biopharmaceutical industry. The company focuses on delivering first- and best-in-class therapies that address critical unmet medical needs, particularly in the areas of pulmonary and inflammatory diseases. Insmed has developed a comprehensive portfolio of both approved and investigational medicines, with various programs currently in the pipeline.

The company’s innovative spirit extends into the realm of cutting-edge drug discovery, which plays a crucial role in the advancement of treatment modalities that promise to have a significant impact on patient care. Specializing in challenging conditions, Insmed’s commitment to patient well-being is reflected in their progress with a therapy that has successfully received regulatory approval in major global markets including the United States, Europe, and Japan. This particular therapy aims to treat chronic and debilitating lung diseases, underscoring Insmed’s pivotal role in the biopharmaceutical landscape.

Moreover, Insmed continues to explore early-stage programs that encompass a vast array of revolutionary technologies. These include, but are not limited to, gene therapy and artificial intelligence-driven protein engineering, all aimed at unlocking new possibilities for therapeutic developments.

Headquartered in Bridgewater, New Jersey, Insmed has established a footprint that spans across the United States, Europe, and Japan, boasting research facilities that facilitate a dynamic environment for innovative studies. The company has received accolades as one of the best employers within the biopharmaceutical sector, having been recognized for four consecutive years as the number one Science Top Employer.

Individuals interested in the healthcare sector will find the upcoming BofA Securities conference a vital platform for gaining insights into Insmed's strategies and future directions. By attending or viewing the presentation subsequently, viewers will gain access to valuable updates regarding projects designed to meet significant medical needs.

For more information on Insmed, please visit their official website at www.insmed.com. Should you have inquiries regarding the conference or Insmed's operations, the investor relations team is available for contact. Investors can reach out to Bryan Dunn, Vice President of Investor Relations, or connect with Claire Mulhearn, Vice President of Corporate Communications, for any media-related questions.

In summary, Insmed Incorporated stands at the vanguard of biopharmaceutical innovation, determined to bring transformative health solutions to those in need. Keep an eye on the BofA Securities 2025 Health Care Conference; it promises to be an exciting opportunity for both the company and its audience.